Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes fasting during Ramadan: A meta-analysis - PubMed
4 days ago
- #Ramadan fasting
- #SGLT2 inhibitors
- #Type 2 diabetes
- SGLT2 inhibitors (SGLT2i) are widely used for managing type 2 diabetes (T2D), but their safety during Ramadan fasting is uncertain.
- A meta-analysis of 12 studies (3,625 subjects) compared SGLT2i with other glucose-lowering drugs during Ramadan fasting.
- SGLT2i users had higher risks of postural dizziness, hypotension, and sodium loss but lower risk of symptomatic hypoglycemia.
- SGLT2i showed greater reductions in systolic and diastolic blood pressure compared to non-SGLT2i users.
- No significant differences were found in glycated hemoglobin, body weight, or renal function between the two groups.
- Risks of dehydration, dizziness, volume depletion, severe hypoglycemia, and genitourinary infections were similar in both groups.
- SGLT2i may be generally safe for T2D patients fasting during Ramadan, but results should be interpreted cautiously.
- Large randomized trials are needed to confirm safety, especially for high-risk groups.